| Typicality: | 0.572 |
| Saliency: | 0.374 |
| at the time of designation | 4 | temporal |
| centrally | 2 | location |
| for treating pancreatic cancer | 2 | purpose |
| medicine → be authorised in → the eu | 12 |
| medicine → be authorised in → the 27 eu member states | 4 |
| medicine → be authorised in → the european union | 4 |
| medicine → be authorised at → a european union level | 3 |
| medicine → be authorised in → the european economic area | 3 |
| negative | neutral | positive |
| 0.069 | 0.759 | 0.172 |
| Raw frequency | 26 |
| Normalized frequency | 0.374 |
| Modifier score | 1.000 |
| Perplexity | 165.772 |